Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ReCode Therapeutics logo — Powering the next wave of genetic medicines through superior...

ReCode Therapeutics

Powering the next wave of genetic medicines through superior delivery

Founded 2015 United States United States 58 employees Series B Total: $347.50M Biopharma, Biotechnology +1

General Information

Company Name ReCode Therapeutics
Founded Year 2015
Location United States United States
Founders / Decision Makers
Team member
Employees 58
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, B2D, Platform
Revenue Model Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with ReCode Therapeutics. To contact ReCode Therapeutics, visit recodetx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ReCode Therapeutics compare?

A PDF of ReCode Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ReCode Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ReCode Therapeutics

ReCode Therapeutics, founded in 2015, is leading innovations in the biopharma sector with its focus on genetic medicines. Based in the United States, this clinical-stage company is setting a benchmark in the Biotechnology and Pharmaceutical industries.

With the slogan "Powering the next wave of genetic medicines through superior delivery," ReCode Therapeutics leverages its proprietary Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) platform to enhance precision drug delivery beyond traditional liver targets. This advanced delivery system positions ReCode as a frontrunner in the emerging field of mRNA and gene correction therapeutics.

The company secured a significant $15.00M grant investment on 01 November 2024, funded by the Cystic Fibrosis Foundation, underscoring confidence in its innovative approach. Investors seeking impactful entry into the genetic medicine market may find ReCode Therapeutics a promising opportunity poised for substantial growth and advancement.

Business keywords: Genetic Medicines, mRNA Therapeutics, Gene Correction, Lipid Nanoparticles, Selective Organ Targeting, SORT Platform, Genetic Delivery Systems, Non-Viral Delivery, Cystic Fibrosis, Primary Ciliary Dyskinesia, Genetic Respiratory Diseases, Clinical-Stage Company

Services & Products

Targeted Delivery of Genetic Medicines
Development of Rare Disease Therapeutics
SORT Lipid Nanoparticle Platform

Target Customers

Patients with Genetically Defined Diseases Healthcare Providers Biotech and Pharmaceutical Partners

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $15.00M 1
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation
01 Nov 2024
Series B $50.00M 12
Amgen Ventures OrbiMed Osage University Partners
Amgen Ventures, OrbiMed +10
01 Sep 2023
Series B $120.00M 7
Amgen Ventures AyurMaya EcoR1 Capital
Amgen Ventures, AyurMaya +5
01 Jun 2022
Series B $80.00M 12
OrbiMed Osage University Partners Colt Ventures
OrbiMed, Osage University Partners +10
01 Oct 2021
Series A $80.00M 5
OrbiMed Colt Ventures Vida Ventures
OrbiMed, Colt Ventures +3
01 Mar 2020
Seed $2.00M -
01 Feb 2019
Seed $500.00K -
01 Jan 2017
Spinout Undisclosed 1
The University of Texas Southwestern Medical School
01 Jan 2015

ReCode Therapeutics Alternatives & Competitors

View All Alternatives
ReCode Therapeutics vs
BreezeBio
BreezeBio United States

Genetic Medicine Delivered

Series A
65 employees
Biotechnology, Health and Wellness
Compare ReCode Therapeutics vs BreezeBio
ReCode Therapeutics vs
Rampart Bioscience
Rampart Bioscience United States

Leading a new era of effective, safe and accessible gene medicines.

Series A
28 employees
Biopharma, Biotechnology
Compare ReCode Therapeutics vs Rampart Bioscience
ReCode Therapeutics vs
ADARx Pharmaceuticals Inc.
ADARx Pharmaceuticals Inc. United States

Our vision is to provide effective and safe RNA therapeutics to patients who suffer from intractable...

Series C
94 employees
Biotechnology, Health Care
View all alternatives

FAQ About ReCode Therapeutics

Powering the next wave of genetic medicines through superior delivery
ReCode Therapeutics was founded in 2015.
ReCode Therapeutics is headquartered in United States.
ReCode Therapeutics operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Genetic Medicines, mRNA Therapeutics, Gene Correction and Lipid Nanoparticles. Its customers include Patients with Genetically Defined Diseases, Healthcare Providers and Biotech and Pharmaceutical Partners.
ReCode Therapeutics has a B2B, B2D and Platform business model. Its revenue comes from Licensing and Project Based.
ReCode Therapeutics has approximately 58 employees.
ReCode Therapeutics has completed 8 funding rounds, raising a total of $347.50M. The latest funding stage is Series B.
ReCode Therapeutics offers: Targeted Delivery of Genetic Medicines, Development of Rare Disease Therapeutics, SORT Lipid Nanoparticle Platform.
Top alternatives and competitors to ReCode Therapeutics include BreezeBio, Rampart Bioscience, ADARx Pharmaceuticals Inc., AusperBio, Arrakis Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ReCode Therapeutics and BreezeBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ReCode Therapeutics, https://bouncewatch.com/company/recode-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout